Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 136Head and Neck Neoplasms 96Squamous Cell Carcinoma of Head and Neck 89Carcinoma, Non-Small-Cell Lung 58Colonic Neoplasms 44Rectal Neoplasms 38Neoplasm Metastasis 34Neoplasms 28Pancreatic Neoplasms 24Lung Neoplasms 18Carcinoma, Squamous Cell 18Stomach Neoplasms 15Tongue Neoplasms 13Esophageal Neoplasms 13Salivary Gland Neoplasms 11Recurrence 10Breast Neoplasms 10Laryngeal Neoplasms 9Mouth Neoplasms 8Esophageal Squamous Cell Carcinoma 8Carcinoma 8Adenocarcinoma Of Esophagus 8Adenocarcinoma of Lung 7Neoplasms, Squamous Cell 6Hypopharyngeal Neoplasms 6Carcinoma, Renal Cell 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Oropharyngeal Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Hepatocellular 5

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × Cetuximab × Clear all
NCT01451632 2016-09-08

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
48 enrolled 14 charts
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡